XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

  • STATUS
    Recruiting
  • End date
    Jun 30, 2024
  • participants needed
    85
  • sponsor
    Xencor, Inc.
Updated on 7 June 2022

Summary

This Phase 2 study will investigate the safety and clinical activity of XmAb20717 alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer (mCRPC) who have been treated with at least 2 prior lines of anticancer therapy.

Description

Detailed Description:

This is a Phase 2, open-label, multiple-dose, multiple-arm, parallel assignment study in patients with mCRPC who have progressed after treatment with at least 2 prior lines of anticancer therapy. It will enroll subjects into one of 5 molecularly defined cohorts based on the results of acceptable, documented prior diagnostic testing:

  • Cohort A: Aggressive variant (anaplastic) adenocarcinoma of the prostate (AVPCa)
  • Cohort B: Homologous recombination deficient (HRD)/cyclin-dependent kinase 12 (CDK12) mutation positive tumors that have progressed on poly-adenosine diphosphate ribose polymerase inhibitors (HRD/CDK12 PARP Progressors)
  • Cohort C: HRD/CDK12 mutation positive tumors not previously treated with PARP inhibitors (HRD/CDK12 PARP Naïve)
  • Cohort D: Microsatellite instability-high (MSI-H) or mismatch repair deficient (MMRD) tumors (MSI-H/MMRD)
  • Cohort E: No Targetable Mutations

Subjects will receive XmAb20717 alone (Cohort D) or in combination with standard therapy (XmAb20717 + carboplatin + cabazitaxel [or docetaxel if no prior treatment]: Cohorts A, B, and E; XmAb20717 + olaparib: Cohort C).

Details
Condition Metastatic Castration-Resistant Prostate Cancer
Treatment XmAb20717 + carboplatin + cabazitaxel, XmAb20717 + olaparib, XmAb20717 monotherapy
Clinical Study IdentifierNCT05005728
SponsorXencor, Inc.
Last Modified on7 June 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Able to provide written informed consent
Adult (age ≥ 18 years)
Histologically confirmed diagnosis of carcinoma of the prostate
Documented progressive mCRPC based on at least one of the following criteria
PSA progression, defined as at least 2 rises in PSA with a minimum of a 1 week interval (1.0 ng/mL is the minimal starting value if confirmed rise is the only indication of progression)
Soft-tissue progression per RECIST 1.1
Progression of bone disease (evaluable disease) or 2 or more new bone lesions by bone scan
Progression after treatment with at least 2 prior lines of anticancer therapy approved
for treatment of metastatic prostate cancer; prior treatment of subjects in
Cohort D (MSI-H or MMRD) must include a checkpoint inhibitor approved by FDA
Prior targeted or whole exome sequencing panel performed by CLIA-certified laboratory
documenting
for that indication
Cohort A (AVPCa) - Aggressive variant prostate cancer
Subjects who did not have a surgical orchiectomy must be on androgen suppression treatment (eg, luteinizing hormone-releasing hormone agonist) with castrate level of testosterone (≤ 50 ng/dL) and be willing to continue the treatment throughout the study
Cohort B or C (HRD) - Homologous recombination deficient (HRD) tumor
Cohort D (MSI-H/MMRD) - Microsatellite instability-high (MSI-H) or mismatch repair deficient (MMRD) tumors (MSI-H/MMRD)
Cohort E (No Targetable Mutations) - Not eligible for Cohorts A, B, C, or D
Evaluable disease according to PCWG3 criteria
Adequate archival metastatic tumor tissue or agree to undergo a biopsy of at least 1 metastatic site (fresh biopsy of primary prostate is only allowed if there is clear local disease and no other measurable disease site or biopsiable bone lesion)
ECOG performance status of 0 or 1
Able and willing to complete the study according to the study schedule

Exclusion Criteria

Currently receiving anticancer therapies other than androgen deprivation
therapy
Treatment with any other anticancer therapy within 2 weeks of the start of study drug (ie, other immunotherapy, chemotherapy, radiation therapy, etc.)
Prior treatment with any cytotoxic T-lymphocyte-associated protein (CTLA4), PD1, PDL1, or programmed cell death ligand 2 (PDL2) directed immunotherapy, except subjects in Cohort D, who will have had prior FDA-approved checkpoint inhibitor therapy
Grade 4 immune-mediated adverse events related to prior immunotherapy (applicable to subjects eligible for Cohort D)
Have known active central nervous system metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are radiologically stable, ie, are without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), are clinically stable, and are without requirement of steroid treatment for at least 14 days prior to first dose of study treatment
Failure to recover from any toxicity related to previous anticancer treatment to ≤ Grade 2
Platelet count < 100 × 109/L
Hemoglobin level ≤ 9.0 g/dL
Absolute neutrophil count ≤ 1.7 × 109 for subjects who will receive cabazitaxel; < 1.0 × 109/L for all others
Estimated creatinine clearance < 50 mL/minute calculated by the Cockcroft Gault or Modification of Diet in Renal Disease formulas
Aspartate aminotransferase at screening > 3 × upper limit of normal (ULN) for subjects without known liver involvement by tumor or > 5 × ULN for subjects with known liver involvement by tumor
Alanine aminotransferase at screening > 3 × ULN for subjects without known liver involvement by tumor or > 5 × ULN for subjects with known liver involvement by tumor
Active known or suspected autoimmune disease (except vitiligo; type 1 diabetes mellitus or residual hypothyroidism due to an autoimmune condition that is treatable with hormone replacement therapy only; psoriasis, atopic dermatitis, or another autoimmune skin condition that is managed without systemic therapy; or arthritis that is managed without systemic therapy beyond oral acetaminophen and nonsteroidal anti-inflammatory drugs)
Bilirubin ≥ 1.5 × ULN (unless prior diagnosis and documentation of ongoing hemolysis or Gilbert's syndrome has been made)
Have any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within 14 days prior to first dose of study drug (except inhaled or topical corticosteroids or brief courses of corticosteroids given for prophylaxis of contrast dye allergic response). Subjects who are currently taking prednisone from a previous prostate cancer therapy will be permitted to enroll in the study
Receipt of an organ allograft
History or evidence of any other clinically unstable/uncontrolled disorder, condition, or disease other than their primary malignancy that, in the opinion of the Investigator, would pose a risk to patient safety or interfere with study evaluations, procedures, or completion
Evidence of any serious bacterial, viral, parasitic, or systemic fungal infections within the 30 days prior to the first dose of study drug
Receipt of a live-virus vaccine within 30 days prior to the first dose of study drug (seasonal flu vaccines that do not contain live virus are permitted)
Known history of left ventricular ejection fraction ≤ 40%
Positive test for hepatitis C RNA (a subject who is hepatitis C virus [HCV] antibody positive but HCV RNA negative due to documented, curative prior antiviral treatment or natural resolution is eligible)
Positive test for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb; a subject whose HBsAg is negative and HBcAb is positive may be enrolled if a hepatitis B virus [HBV] DNA test is negative and the subject is retested for HBsAg and HBV DNA every 2 months)
A human immunodeficiency virus (HIV) positive subject with CD4+ T-cell (CD4+) counts < 350 cells/μL, or an HIV viral load greater than 400 copies/mL, or a history of an AIDS (acquired immunodeficiency syndrome)-defining opportunistic infection within the past 12 months, or who has not been on established antiretroviral therapy (ART) for at least 4 weeks prior to initiation of study drug dosing. (Effective ART is defined as a drug, dosage, and schedule associated with reduction and control of the viral load.)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note